Skip to content

Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata

Efficacy of Combined CO2 Fractional Laser With Bimatoprost 0.03% in Treatment of Alopecia Areata

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05600673
Enrollment
30
Registered
2022-10-31
Start date
2019-01-01
Completion date
2021-05-01
Last updated
2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Keywords

Alopecia areata, Bimatoprost, CO2 Fractional Laser

Brief summary

The goal of this study is to evaluate the efficacy and safety of combined CO2 fractional laser with Bimatoprost 0.03% as novel treatment of alopecia areata. The main question to study is will the bimatoprost facilitate hair growth if added to fractional CO2 laser treatment in Alopecia areata.

Detailed description

The study included 30 patients who were diagnosed clinically and dermoscopically as alopecia areata with age ranged between 16-55 years. The patients are divided into 2 groups: Group I, received fractional laser sessions with immediate and daily Bimatoprost application and Group II, received only frequent Laser sessions. Laser sessions were given to each patch once every 3 weeks, the procedure was repeated for 3 times.

Interventions

Topical Bimatoprost 0.03% solution

CO2 fractional laser treatment

Sponsors

Ahmed Hassan Nouh MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

In this design, subjects are randomized to 2 study arms and each study arm will be allocated a different intervention. After randomization each participant will stay in their assigned treatment arm for the duration of the study.

Eligibility

Sex/Gender
ALL
Age
16 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Patients with alopecia areata of the scalp (multilocuolaris or single patch). * Patient aged from 16- 55 years old in both sex. * Other treatment wash out period is two months.

Exclusion criteria

* Ophiasis pattern and other patterns of alopecia areata. * Chronic diseases of liver, heart, kidney and blood * Pregnant women * Infections of skin in site of intervention

Design outcomes

Primary

MeasureTime frameDescription
Hair regrowth9 weeksEfficacy of treatment assessed using a prognostic scoring system proposed by Mcdonald Hull and Norris for density, pigmentation, and texture of growing hair. Grade 1 - Regrowth of vellus hair Grade 2 - Regrowth of sparse pigmented terminal hair Grade 3 - Regrowth of terminal hair with patches of alopecia Grade 4 - Regrowth of terminal hair on scalp

Secondary

MeasureTime frameDescription
Side effects9 weeksThe patients were asked about any side effects noticed every session by questionnaire. The patient satisfaction scale: - the patients were asked at final visit to rate the overall satisfaction according to whether the patient was not satisfied, slightly satisfied, satisfied or very satisfied. The patients were asked to report any complications as; erythema, pain, ulceration, burning sensation, ecchymosis, infection, post-inflammatory hyperpigmentation or any allergic manifestations.
Follow up assessment9 weeksThe patients were followed up 3 weeks after the end of treatment sessions to detect any recurrence, complications or worsening of the lesions & final results of treatment.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026